Parker Cassidy's Location
Lexington, Massachusetts, United States, United States
Parker Cassidy's Contact Details
Parker Cassidy work email
- Valid
- Valid
- Valid
- Valid
Parker Cassidy personal email
n/a
Parker Cassidy phone numbers
About Parker Cassidy
Life science investor with 20 years of operating experience in diagnostics, tools and devices.
Parker Cassidy Work Experience Details
-
PartnerSands Capital Aug 2021 - PresentArlington, Va, Us -
Board MemberCytovale Aug 2023 - PresentSan Francisco, Ca, UsCytovale is committed to improving human health by pioneering early detection technologies powered by insightful assessment of immune activation. Comprised of an extraordinary team of life scientists, engineers, clinicians and dreamers, Cytovale intends to accelerate the time it takes to get from triage to life-saving therapies. Learn more about Cytovale and request to implement IntelliSep® in your hospital or care setting through cytovale.com -
Board MemberBeta Bionics Aug 2023 - PresentIrvine, Ca, UsBeta Bionics is a medical technology company focused on the design, development, and commercialization of its iLet Bionic Pancreas in both the single hormone and bi-hormonal configurations. The iLet Bionic Pancreas platform is designed to use adaptive, self-learning, control algorithms, together with continuous glucose monitoring and pump technology, to autonomously compute and administer doses of insulin and/or glucagon and mimic the body’s natural ability to maintain tight glycemic control, relieving some of the burden of living with diabetes. To learn more, visit www.betabionics.com. -
Board ObserverCleerly Jul 2022 - PresentDenver, Colorado, UsCleerly is creating a new standard of care for screening for and treating coronary artery disease through its AI-enabled software solutions. -
Board MemberNucleix Ltd. Nov 2021 - PresentRehovot, Merkaz, IlNucleix is applying its ultra sensitive, low cost methylation detection technology to cancer screening. -
Board ObserverExo Sep 2020 - PresentSanta Clara, California, UsExo is launching a point of care ultrasound platform (hardware and associated software) to enable widespread use of best in class imaging. -
Board MemberSelux Diagnostics, Inc Jun 2018 - PresentBoston, Massachusetts, UsSeLux Diagnostics has developed a novel diagnostic platform for rapid and comprehensive phenotypic Antibiotic Susceptibility Testing (AST) that lowers healthcare costs and improves health outcomes. The SeLux proprietary system consists of a fully automated instrument, assay approach and learning algorithm. -
Board Member, Board ObserverQvella Corporation Nov 2015 - Feb 2024Richmond Hill, Ontario, CaQVella's FAST ID platform delivers rapid (<1hr) detection of blood stream infections direct from whole blood.Director: 2015-2021Board Observer: 2021-Present -
Board MemberNanoview Biosciences Nov 2015 - May 2022Advisor, Investor and Director from the time of spinning out from BU through to a strategic sale to Unchained Labs. NanoView Biosciences enables sensitive and efficient detection of exosomes and extracellular vesicles (EVs) and other nanoparticles direct from biological samples.
-
Principal, Diagnostics And ToolsRa Capital Management, L.P. Apr 2020 - Jun 2021Boston, Ma, Us -
Chief Commercial Officer (Cco)Farcast Biosciences Nov 2015 - Apr 2020Bengaluru, Karnataka, InLed the commercial strategy development and implementation for a novel oncology histoculture platform to predict patient response and inform therapeutic development. Built the worldwide biopharma commercial strategy and team that drove rapid commercial uptake. Developed and implemented the worldwide clinical strategy centered on evidence development to drive adoption and reimbursement. Built the team that drove the ANCERS study to be implemented across >50 oncology centers. When the interim analysis from ANCERS showed poor performance of the platform technology, wound down the commercial efforts and led root cause analysis and corrective actions. Formulated a revised strategic direction and executed key partnerships to enable the company to rebuild the offering. Instrumental in raising two rounds of venture funding totaling $70M. -
Member, Board Of DirectorsQuad Technologies Jul 2015 - Jul 2018Woburn, Ma, UsBoard member from Series A funding through to strategic sale to Bio-Techne. Quad's bioprocessing technology enables magnetic bead free T-cell separation and activation for CAR-T therapies. -
EirRa Capital Management, Llc Jan 2015 - Oct 2015Boston, Ma, UsRA Capital is a healthcare crossover fund based in Boston that invests in development-stage private and public drug, medical device, and diagnostic companies.
-
Vice President, Continuous Glucose MonitoringBd Feb 2011 - Feb 2014Franklin Lakes, New Jersey, UsReporting to the President, Diabetes Care, I was the General Manager leading an internal innovation from startup (concept) through development, including two human trials, for a Class III medical device intended to be BD's breakthrough entry into an emerging, potential $billion+ category.* Recruited and built a new cross functional team.* Led the development of a more integrated diabetes strategy, leveraging the planned informatics capabilities of our new glucose monitoring system.* Developed worldwide launch plan, with an emphasis on market access and reimbursement in the EU with a supporting health economic plan.* Key leader in a team that overhauled BD's corporate wide innovation system - from ideation through execution. -
Managing Director, Infectious Disease Molecular DiagnosticsBd Nov 2009 - Feb 2011Franklin Lakes, New Jersey, UsReporting to the General Manager of BD's $850M Infectious Disease Diagnostics unit, I was the General Manager leading the integration of BD's $275M acquisition of HandyLab.* Launched BD MAX - the first fully automated molecular diagnostic system that enables both batch and on-demands testing - at the time, BD's largest innovation initiative.* Developed novel portfolio strategy that leveraged outside partners for development of new assays.* Secured collaborative contract with minimum instrument and assay purchase commitments of $35M.
-
Director, Product And Business DevelopmentBd Sep 2006 - Nov 2009Franklin Lakes, New Jersey, UsReporting to the General Manager of BD's Molecular Diagnostics business, I was a central leader in developing and delivering on an integrated instrument and assay portfolio to transform the business into a more comprehensive infectious disease leader.* Managed and mentored a group of core team leaders. * Developed portfolio strategy and resource allocation tools for $40M in new product development spending.* Led the business development negotiations including technology licensing and business partnerships to enable the portfolio development.* Championed acquisition of HandyLab and led the due diligence team.
-
Vice President, General Manager, Business Segment LeaderSerologicals, (Previously Upstate Biotechnology) - Acquired By Millipore 2000 - 2006UsExecutive in the research and drug discovery tools division of Serologicals, driving >20% annual growth in multiple product categories spanning the Upstate, Chemicon and LINCO brands.Led $65M acquisition of LINCO and subsequent integration.Business leader accountable for $70M in annual revenue.Prior roles include:Sr. Director, Business Segment Management, Business Segment Director, Business Development Manager. -
Manufacturing Engineer Development ProgramPratt & Whitney 1996 - 1998East Hartford, Ct, UsA select rotational program designed to develop future manufacturing leaders. Completed rotations in Shop Floor Supervision, Manufacturing Engineering and International Supply Chain Management.
Parker Cassidy Skills
Cross Functional Team Leadership
Biotechnology
Medical Devices
Business Development
Leadership
Commercialization
Life Sciences
Management
Product Launch
Business Strategy
Fda
Strategy
Molecular Diagnostics
Infectious Diseases
Due Diligence
Lifesciences
Manufacturing
Employee Engagement
Marketing Strategy
Ip
Ngs
Cross Functional Relationships
Global Business Management
Marketing
New Business Development
Parker Cassidy Education Details
-
University Of Virginia Darden School Of BusinessMaster Of Business Administration (Mba) -
Boston UniversityMechanical Engineering
Frequently Asked Questions about Parker Cassidy
What company does Parker Cassidy work for?
Parker Cassidy works for Sands Capital
What is Parker Cassidy's role at the current company?
Parker Cassidy's current role is Partner, Sands Capital Management.
What is Parker Cassidy's email address?
Parker Cassidy's email address is parker.cassidy@bd.com
What is Parker Cassidy's direct phone number?
Parker Cassidy's direct phone number is (781)-935*****
What schools did Parker Cassidy attend?
Parker Cassidy attended University Of Virginia Darden School Of Business, Boston University.
What skills is Parker Cassidy known for?
Parker Cassidy has skills like Cross Functional Team Leadership, Biotechnology, Medical Devices, Business Development, Leadership, Commercialization, Life Sciences, Management, Product Launch, Business Strategy, Fda, Strategy.
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial